Lifestance Health Group, Inc. (LFST)

In November and December 2025, BMO Capital and Barclays initiated "Outperform" and "Overweight" ratings, respectively. In February 2026, Keybanc, UBS, and Canaccord Genuity reiterated or maintained positive ratings, with UBS raising its price target to $12.00. On May 7, 2026, LifeStance reported strong first-quarter results, exceeding expectations and raising full-year guidance, causing the stock to surge. However, on May 8, 2026, the stock declined following the announcement of a secondary public offering. In late April 2026, LifeStance Health was added to the S&P SmallCap 600 and S&P Composite 1500 indices. Insider selling has also been noted.

LifeStance Health Group experiences demand seasonality, with revenue split approximately 50/50 between the first and second halves of the year, the second half being modestly higher. Demand typically peaks every January, and this trend is expected to continue.

LifeStance Health Group, Inc. is a mental healthcare company providing outpatient mental health services, including psychiatric evaluations, psychological testing, and therapy. They treat various mental health conditions using evidence-based approaches, emphasizing a personalized, digitally-powered patient experience and in-network insurance relationships.

As of March 31, 2026, LifeStance Health Group employs over 8,300 psychiatrists, advanced practice nurses, psychologists, and therapists. The company operates across 33 states and more than 550 centers. As of March 27, 2024, there were 577 LifeStance Health clinics in the United States, with California having the most locations (50 clinics), followed by Illinois (44) and Colorado (39).

LifeStance Health aims to improve access to mental healthcare, highlighting positive patient feedback with a high net promoter score and Google rating. An outcomes study showed significant improvement in anxiety and depression among patients. However, a report in October 2023 uncovered complaints regarding overbilling and fraudulent practices, leading to a negative rating from the Better Business Bureau.

LifeStance Health Group's ownership is predominantly institutional. As of July 25, 2025, institutional investors collectively owned approximately 87.3% of the company's shares, with individual investors accounting for about 9.0%. Major institutional shareholders include TPG GP A, LLC, Summit Partners L.P., FMR LLC, BlackRock, Inc., and Vanguard Group Inc. TPG Group Holdings SBS Advisors Inc. is the largest individual shareholder, owning 45.20% of the company.